Neurable announced that it raised $13 million to support its one-of-a-kind, non-invasive brain-computer interface (BCI) technology. Ultratech Capital Partners, TRAC, Pace Ventures and Metaplanet contributed to the funding round. It brings the Boston-based companyโs total funding over $30 million to date. https://lnkd.in/eQH6dYMc #SkillsAlliance #Pharma #MedicalDevices
Skills Allianceโs Post
More Relevant Posts
-
Exciting news! Scinai Immunotherapeutics Ltd. ๐ซ๐๐๐๐ข๐ฏ๐๐ฌ ๐๐ง ๐ฎ๐ฉ๐๐๐ญ๐๐ ๐๐๐ญ๐ญ๐๐ซ ๐จ๐ ๐๐ง๐ญ๐๐ง๐ญ (๐๐จ๐) ๐๐ซ๐จ๐ฆ ๐ญ๐ก๐ European Investment Bank (EIB) ๐จ๐ฎ๐ญ๐ฅ๐ข๐ง๐ข๐ง๐ ๐ฌ๐ฉ๐๐๐ข๐๐ข๐ ๐ญ๐๐ซ๐ฆ๐ฌ ๐๐จ๐ซ ๐๐จ๐ง๐ฏ๐๐ซ๐ญ๐ข๐ง๐ ๐ญ๐ก๐ ๐ฆ๐๐ฃ๐จ๐ซ๐ข๐ญ๐ฒ ๐จ๐ ๐ญ๐ก๐ ๐๐๐โ๐ฌ ๐ฅ๐จ๐๐ง ๐ข๐ง๐ญ๐จ ๐๐ช๐ฎ๐ข๐ญ๐ฒ ๐ญ๐ก๐ซ๐จ๐ฎ๐ ๐ก ๐ฉ๐ซ๐๐๐๐ซ๐ซ๐๐ ๐ฌ๐ก๐๐ซ๐๐ฌ. - The shares are convertible into American Depositary Shares (ADSs), representing 19.5% of the fully diluted capital of the company at the time of closing. Notably, there are no anti-dilution rights. - The updated LoI does not require a variable remuneration, which in the previous LOI included a 3% royalty on the Company's revenues and 5% of any equity raise up to a limit of EUR 70 million, nor does it provide for mandatory dividends or mandatory redemption. - The loan amount that would be converted is approximately $28 million, while approximately $270,000 will stay as a loan payable on Dec 31st, 2031. ๐๐ก๐ข๐ฌ ๐ฌ๐ญ๐ซ๐๐ญ๐๐ ๐ข๐ ๐ฆ๐จ๐ฏ๐ ๐๐จ๐ฎ๐ฅ๐ ๐ข๐ฆ๐ฆ๐๐๐ข๐๐ญ๐๐ฅ๐ฒ ๐๐ฅ๐ข๐ฆ๐ข๐ง๐๐ญ๐ ๐ญ๐ก๐ ๐ฌ๐ก๐๐ซ๐๐ก๐จ๐ฅ๐๐๐ซ๐ฌโ ๐๐๐๐ข๐๐ข๐ญ ๐จ๐ $๐.๐ ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง (๐๐ฌ ๐จ๐ ๐๐๐ซ๐๐ก ๐๐๐ฌ๐ญ, ๐๐๐๐) ๐๐ง๐ ๐๐ซ๐๐๐ญ๐ ๐ ๐ฌ๐ฎ๐ซ๐ฉ๐ฅ๐ฎ๐ฌ ๐ข๐ง ๐ฌ๐ก๐๐ซ๐๐ก๐จ๐ฅ๐๐๐ซ๐ฌโ ๐๐ช๐ฎ๐ข๐ญ๐ฒ. ๐ป๐๐๐๐ ๐๐๐, #๐ฌ๐ฐ๐ฉ ๐๐๐ ๐๐๐๐ ๐๐๐๐ ๐๐ ๐๐๐๐๐๐ ๐๐๐๐ ๐๐ Scinai Immunotherapeutics Ltd. ๐๐๐ ๐๐๐ ๐๐๐๐๐๐. ๐ป๐๐๐ ๐๐ ๐ ๐๐๐๐๐๐๐ ๐๐๐๐๐ ๐๐๐๐๐ ๐๐ ๐๐๐ ๐น&๐ซ ๐๐๐ ๐ช๐ซ๐ด๐ถ ๐๐๐๐๐๐๐๐. Read the press release >>https://lnkd.in/dqYXgxzT #NASDAQ #EIB #growth #biotech #partnership #companynews #pressrelease
To view or add a comment, sign in
-
-
Thoughts on this? >> Alexis Borisy and Zach Weinberg's Curie.Bio secures $380M to support portfolio's Series A rounds >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #productmarketing #healthcare #biotech
Alexis Borisy and Zach Weinberg's Curie.Bio secures $380M to support portfolio's Series A rounds
https://endpts.com
To view or add a comment, sign in
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Alexis Borisy and Zach Weinberg's Curie.Bio secures $380M to support portfolio's Series A rounds >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #healthcare #pharmaceutical
Alexis Borisy and Zach Weinberg's Curie.Bio secures $380M to support portfolio's Series A rounds
https://endpts.com
To view or add a comment, sign in
-
Launched by veteran biotech venture capitalist Alexis Borisy, EQRx started up in early 2020 with grand plans to reimagine how prescription drugs are developed and priced. The company claimed it could invent or license similar, but more effective competitors to top-selling specialty medicines, such as those for cancer, and sell them for less โ a vision EQRx executives used to raise more than $2 billion in funding. REVOLUTION Medicine is a University of Illinois Urbana-Champaign start-up created under EnterpriseWorks in 2014 as a company funded by Illinois Ventures and Third Rock with superstar faculty Martin D. Burke, Michael Fischbach, and Kevan Shokat (UCSF) originally developing low toxicity Amphotericin analogs. But a reorganization saw the Ampho technology returned to the university (Relicensed to Deerfield Partners) as REVOLUTION repositioned itself by purchasing a KRAS biotech company. Now with the merger REVOLUTION acquires a massive amount of cash to develop in in-licensed technologies. https://lnkd.in/gA9bfjAz
Updated: EQRx acquired by Revolution Medicines, another Alexis Borisy company, in all-stock deal
https://endpts.com
To view or add a comment, sign in
-
A look at biopharmaโs most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis. Unpartnered assets - should more prominent players swoop in or swerve them entirely? The Evaluate Vantage team has run a new analysis on some of the most significant unpartnered assets in the pipeline to look at which might be destined for a deal and which are headed for a solo journey. This is an emerging area of interest from private investors and mid-size Pharma. There might be more activity coming up later this year. https://lnkd.in/d-s5C8Ww
Unpartnered assets: on the shelf or hidden treasure?
evaluate.com
To view or add a comment, sign in
-
Another important milestone is on its way for completion. Removing an overhanging debt of $28 million, in exchange for preferred shares convertible to shares representing 19.5% of our share capital. Once fully signed this would mean that the bank believes it will probably have a better IRR by converting $28 million loan to roughly 20% of our company! it is a massive validation to our R&D and CDMO strategy! #debttoequity #restructuring #refinancing #EIB #EuropeanInvetsmentBank
Exciting news! Scinai Immunotherapeutics Ltd. ๐ซ๐๐๐๐ข๐ฏ๐๐ฌ ๐๐ง ๐ฎ๐ฉ๐๐๐ญ๐๐ ๐๐๐ญ๐ญ๐๐ซ ๐จ๐ ๐๐ง๐ญ๐๐ง๐ญ (๐๐จ๐) ๐๐ซ๐จ๐ฆ ๐ญ๐ก๐ European Investment Bank (EIB) ๐จ๐ฎ๐ญ๐ฅ๐ข๐ง๐ข๐ง๐ ๐ฌ๐ฉ๐๐๐ข๐๐ข๐ ๐ญ๐๐ซ๐ฆ๐ฌ ๐๐จ๐ซ ๐๐จ๐ง๐ฏ๐๐ซ๐ญ๐ข๐ง๐ ๐ญ๐ก๐ ๐ฆ๐๐ฃ๐จ๐ซ๐ข๐ญ๐ฒ ๐จ๐ ๐ญ๐ก๐ ๐๐๐โ๐ฌ ๐ฅ๐จ๐๐ง ๐ข๐ง๐ญ๐จ ๐๐ช๐ฎ๐ข๐ญ๐ฒ ๐ญ๐ก๐ซ๐จ๐ฎ๐ ๐ก ๐ฉ๐ซ๐๐๐๐ซ๐ซ๐๐ ๐ฌ๐ก๐๐ซ๐๐ฌ. - The shares are convertible into American Depositary Shares (ADSs), representing 19.5% of the fully diluted capital of the company at the time of closing. Notably, there are no anti-dilution rights. - The updated LoI does not require a variable remuneration, which in the previous LOI included a 3% royalty on the Company's revenues and 5% of any equity raise up to a limit of EUR 70 million, nor does it provide for mandatory dividends or mandatory redemption. - The loan amount that would be converted is approximately $28 million, while approximately $270,000 will stay as a loan payable on Dec 31st, 2031. ๐๐ก๐ข๐ฌ ๐ฌ๐ญ๐ซ๐๐ญ๐๐ ๐ข๐ ๐ฆ๐จ๐ฏ๐ ๐๐จ๐ฎ๐ฅ๐ ๐ข๐ฆ๐ฆ๐๐๐ข๐๐ญ๐๐ฅ๐ฒ ๐๐ฅ๐ข๐ฆ๐ข๐ง๐๐ญ๐ ๐ญ๐ก๐ ๐ฌ๐ก๐๐ซ๐๐ก๐จ๐ฅ๐๐๐ซ๐ฌโ ๐๐๐๐ข๐๐ข๐ญ ๐จ๐ $๐.๐ ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง (๐๐ฌ ๐จ๐ ๐๐๐ซ๐๐ก ๐๐๐ฌ๐ญ, ๐๐๐๐) ๐๐ง๐ ๐๐ซ๐๐๐ญ๐ ๐ ๐ฌ๐ฎ๐ซ๐ฉ๐ฅ๐ฎ๐ฌ ๐ข๐ง ๐ฌ๐ก๐๐ซ๐๐ก๐จ๐ฅ๐๐๐ซ๐ฌโ ๐๐ช๐ฎ๐ข๐ญ๐ฒ. ๐ป๐๐๐๐ ๐๐๐, #๐ฌ๐ฐ๐ฉ ๐๐๐ ๐๐๐๐ ๐๐๐๐ ๐๐ ๐๐๐๐๐๐ ๐๐๐๐ ๐๐ Scinai Immunotherapeutics Ltd. ๐๐๐ ๐๐๐ ๐๐๐๐๐๐. ๐ป๐๐๐ ๐๐ ๐ ๐๐๐๐๐๐๐ ๐๐๐๐๐ ๐๐๐๐๐ ๐๐ ๐๐๐ ๐น&๐ซ ๐๐๐ ๐ช๐ซ๐ด๐ถ ๐๐๐๐๐๐๐๐. Read the press release >>https://lnkd.in/dqYXgxzT #NASDAQ #EIB #growth #biotech #partnership #companynews #pressrelease
To view or add a comment, sign in
-
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Moderna partners with Blackstone on flu shots, nabbing up to $750M in R&D funding >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharma #pharmaceutical #healthcare
Moderna partners with Blackstone on flu shots, nabbing up to $750M in R&D funding
https://endpts.com
To view or add a comment, sign in
-
Thoughts on this? >> Moderna partners with Blackstone on flu shots, nabbing up to $750M in R&D funding >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #pharma #productmarketing #healthcare
Moderna partners with Blackstone on flu shots, nabbing up to $750M in R&D funding
https://endpts.com
To view or add a comment, sign in
-
January 2, 2024: 2024 will be a landmark year for Cosmos Pharmaceuticals LLC with its revolutionary medication adherence platform introduction to the early adopters! The year kicks off with Cosmos' much-anticipated device, FortisKap, landing in the hands of patients in our study groups. This platform promises to revolutionize medication adherence offering real time dosing timeframes, dosing quantities and predictive risk management. Cosmos will showcase its innovation at the upcoming RESI JPM conference in San Francisco next week and connect with key investors and potential partners. "Most Investable StartUp" recognition: Life Science Nationโs recognition validates Cosmos' potential and supports the company's $1.25M seed capital raise. This funding supports commercialization development and entry into the market. #RESIJPM #RESIJPM24 #RESISANFRAN
To view or add a comment, sign in
-
-
CMC โ it's the point where drug development often goes to fail. โข The manufacturing process โข Repeatability โข Scale-up Nevan Charles Elam, CEO at Rezolute, Inc., explains how his company recruited CMC and commercialization experts as soon as their clinical data showed some real promise. It's been two years since his original #BusinessOfBiotech conversation. Since then, Rezolute has doubled its workforce. In today's episode, he tells host Matthew Pillar how he plans to manage that growth intelligently over the next few years as they approach commercialization of their RZ358 candidate.
Managing Momentum With Rezolute Bio's Nevan Charles Elam, JD
bioprocessonline.com
To view or add a comment, sign in